vs
Side-by-side financial comparison of QuidelOrtho Corp (QDEL) and RANGE RESOURCES CORP (RRC). Click either name above to swap in a different company.
RANGE RESOURCES CORP is the larger business by last-quarter revenue ($786.9M vs $699.9M, roughly 1.1× QuidelOrtho Corp). RANGE RESOURCES CORP runs the higher net margin — 22.8% vs -104.7%, a 127.5% gap on every dollar of revenue. On growth, RANGE RESOURCES CORP posted the faster year-over-year revenue change (18.0% vs -3.7%). Over the past eight quarters, RANGE RESOURCES CORP's revenue compounded faster (14.6% CAGR vs -2.9%).
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide.
Range Resources Corporation is a natural gas exploration and production company, the headquartered is in Fort Worth, Texas. It operates in the Marcellus Formation, where it is the largest land owners.
QDEL vs RRC — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $699.9M | $786.9M |
| Net Profit | $-733.0M | $179.1M |
| Gross Margin | — | 94.5% |
| Operating Margin | -100.7% | — |
| Net Margin | -104.7% | 22.8% |
| Revenue YoY | -3.7% | 18.0% |
| Net Profit YoY | -3583.4% | 88.8% |
| EPS (diluted) | $-10.78 | $0.75 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $786.9M | ||
| Q3 25 | $699.9M | $655.3M | ||
| Q2 25 | $613.9M | $699.6M | ||
| Q1 25 | $692.8M | $846.3M | ||
| Q4 24 | $707.8M | $667.0M | ||
| Q3 24 | $727.1M | $567.9M | ||
| Q2 24 | $637.0M | $513.2M | ||
| Q1 24 | $711.0M | $598.8M |
| Q4 25 | — | $179.1M | ||
| Q3 25 | $-733.0M | $144.3M | ||
| Q2 25 | $-255.4M | $237.6M | ||
| Q1 25 | $-12.7M | $97.1M | ||
| Q4 24 | $-178.4M | $94.8M | ||
| Q3 24 | $-19.9M | $50.7M | ||
| Q2 24 | $-147.7M | $28.7M | ||
| Q1 24 | $-1.7B | $92.1M |
| Q4 25 | — | 94.5% | ||
| Q3 25 | — | 92.5% | ||
| Q2 25 | — | 95.0% | ||
| Q1 25 | — | 93.1% | ||
| Q4 24 | — | 93.7% | ||
| Q3 24 | — | 94.3% | ||
| Q2 24 | — | 93.4% | ||
| Q1 24 | — | 94.7% |
| Q4 25 | — | — | ||
| Q3 25 | -100.7% | — | ||
| Q2 25 | -29.4% | — | ||
| Q1 25 | 4.7% | — | ||
| Q4 24 | -14.2% | — | ||
| Q3 24 | 2.1% | — | ||
| Q2 24 | -18.4% | — | ||
| Q1 24 | -247.3% | — |
| Q4 25 | — | 22.8% | ||
| Q3 25 | -104.7% | 22.0% | ||
| Q2 25 | -41.6% | 34.0% | ||
| Q1 25 | -1.8% | 11.5% | ||
| Q4 24 | -25.2% | 14.2% | ||
| Q3 24 | -2.7% | 8.9% | ||
| Q2 24 | -23.2% | 5.6% | ||
| Q1 24 | -239.9% | 15.4% |
| Q4 25 | — | $0.75 | ||
| Q3 25 | $-10.78 | $0.60 | ||
| Q2 25 | $-3.77 | $0.99 | ||
| Q1 25 | $-0.19 | $0.40 | ||
| Q4 24 | $-2.54 | $0.38 | ||
| Q3 24 | $-0.30 | $0.21 | ||
| Q2 24 | $-2.20 | $0.12 | ||
| Q1 24 | $-25.50 | $0.38 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $98.1M | $204.0K |
| Total DebtLower is stronger | $2.5B | $1.2B |
| Stockholders' EquityBook value | $2.0B | $4.3B |
| Total Assets | $5.7B | $7.4B |
| Debt / EquityLower = less leverage | 1.23× | 0.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $204.0K | ||
| Q3 25 | $98.1M | $175.0K | ||
| Q2 25 | $151.7M | $134.0K | ||
| Q1 25 | $127.1M | $344.6M | ||
| Q4 24 | $98.3M | $304.5M | ||
| Q3 24 | $143.7M | $277.4M | ||
| Q2 24 | $107.0M | $251.1M | ||
| Q1 24 | $78.5M | $343.1M |
| Q4 25 | — | $1.2B | ||
| Q3 25 | $2.5B | $1.2B | ||
| Q2 25 | $2.1B | $1.2B | ||
| Q1 25 | $2.1B | $1.7B | ||
| Q4 24 | $2.1B | $1.7B | ||
| Q3 24 | $2.2B | $1.7B | ||
| Q2 24 | $2.2B | $1.7B | ||
| Q1 24 | $2.2B | $1.8B |
| Q4 25 | — | $4.3B | ||
| Q3 25 | $2.0B | $4.2B | ||
| Q2 25 | $2.8B | $4.1B | ||
| Q1 25 | $3.0B | $3.9B | ||
| Q4 24 | $3.0B | $3.9B | ||
| Q3 24 | $3.2B | $3.9B | ||
| Q2 24 | $3.2B | $3.9B | ||
| Q1 24 | $3.3B | $3.8B |
| Q4 25 | — | $7.4B | ||
| Q3 25 | $5.7B | $7.2B | ||
| Q2 25 | $6.4B | $7.1B | ||
| Q1 25 | $6.5B | $7.4B | ||
| Q4 24 | $6.4B | $7.3B | ||
| Q3 24 | $6.8B | $7.2B | ||
| Q2 24 | $6.7B | $7.3B | ||
| Q1 24 | $6.7B | $7.4B |
| Q4 25 | — | 0.28× | ||
| Q3 25 | 1.23× | 0.29× | ||
| Q2 25 | 0.74× | 0.29× | ||
| Q1 25 | 0.70× | 0.43× | ||
| Q4 24 | 0.72× | 0.43× | ||
| Q3 24 | 0.68× | 0.44× | ||
| Q2 24 | 0.70× | 0.44× | ||
| Q1 24 | 0.68× | 0.46× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-45.5M | $257.5M |
| Free Cash FlowOCF − Capex | $-94.7M | — |
| FCF MarginFCF / Revenue | -13.5% | — |
| Capex IntensityCapex / Revenue | 7.0% | — |
| Cash ConversionOCF / Net Profit | — | 1.44× |
| TTM Free Cash FlowTrailing 4 quarters | $-153.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $257.5M | ||
| Q3 25 | $-45.5M | $247.5M | ||
| Q2 25 | $-46.8M | $336.2M | ||
| Q1 25 | $65.6M | $330.1M | ||
| Q4 24 | $63.7M | $217.9M | ||
| Q3 24 | $117.9M | $245.9M | ||
| Q2 24 | $-97.9M | $148.8M | ||
| Q1 24 | $-700.0K | $331.9M |
| Q4 25 | — | — | ||
| Q3 25 | $-94.7M | — | ||
| Q2 25 | $-84.3M | — | ||
| Q1 25 | $9.4M | — | ||
| Q4 24 | $16.5M | — | ||
| Q3 24 | $71.4M | — | ||
| Q2 24 | $-133.2M | — | ||
| Q1 24 | $-66.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | -13.5% | — | ||
| Q2 25 | -13.7% | — | ||
| Q1 25 | 1.4% | — | ||
| Q4 24 | 2.3% | — | ||
| Q3 24 | 9.8% | — | ||
| Q2 24 | -20.9% | — | ||
| Q1 24 | -9.4% | — |
| Q4 25 | — | — | ||
| Q3 25 | 7.0% | — | ||
| Q2 25 | 6.1% | — | ||
| Q1 25 | 8.1% | — | ||
| Q4 24 | 6.7% | — | ||
| Q3 24 | 6.4% | — | ||
| Q2 24 | 5.5% | — | ||
| Q1 24 | 9.3% | — |
| Q4 25 | — | 1.44× | ||
| Q3 25 | — | 1.72× | ||
| Q2 25 | — | 1.42× | ||
| Q1 25 | — | 3.40× | ||
| Q4 24 | — | 2.30× | ||
| Q3 24 | — | 4.85× | ||
| Q2 24 | — | 5.18× | ||
| Q1 24 | — | 3.60× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
RRC
| Natural Gas Natural Gas Liquids And Oil Sales | $745.5M | 95% |
| Brokered Natural Gas And Marketing | $41.3M | 5% |
